--- title: "BioVie (BIVI) news: going concern, offering and lawsuit" url: "https://aibio.space/companies/biovie/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BIVI going concern, offering and lawsuit news: BioVie prices $12 million public offering of units at $2.00. BioVie Inc. (NASDAQ: BIVI), United States." --- BIVI BioVie Inc. NASDAQ · United States # BioVie (BIVI) news BIVI going concern, offering and lawsuit news Financings · 2026-09-11 ## [BioVie enters sales agreement for up to $6,464,341 of common stock](https://aibio.space/news/biovie-enters-sales-agreement-up-6-464-341-common-stock/) BioVie agreed with A.G.P./Alliance Global Partners to sell up to $6,464,341 of Class A common stock through an at-the-market program, with a 3.0% commission on gross proceeds. ## Latest BioVie news 1. 2026-08-13 Legal [BioVie securities class certified in Nevada; three derivative suits stayed](https://aibio.space/news/biovie-securities-class-certified-nevada-three-derivative-suits-stayed/) The 10-K says the court certified the class on June 18, 2026 in In re BioVie Inc. Securities Litigation. BioVie and unnamed officers are defendants; insurance carries a $2 million deductible. 2. 2026-08-06 Company Updates [BioVie reports topline results from Phase 2 SUNRISE-PD trial in Parkinson's disease](https://aibio.space/news/biovie-reports-topline-results-phase-2-sunrise-pd-trial-parkinsons/) BioVie said bezisterim met its prespecified endpoints in early-stage Parkinson's disease, with improved blood inflammatory markers and better composite clinical outcomes than placebo. 3. 2025-08-11 Financings [BioVie closes public offering of units and warrants with net proceeds of about $10.4 million](https://aibio.space/news/biovie-closes-public-offering-units-warrants-net-proceeds-about-10-4/) ThinkEquity was sole underwriter for 5,620,000 units and 380,000 pre-funded units. Warrants carry a $2.50 exercise price and trade as BIVIW; BioVie plans to use the money for working capital. 4. 2025-08-08 Financings [BioVie prices $12 million public offering of units at $2.00](https://aibio.space/news/biovie-prices-12-million-public-offering-units-2-00/) BioVie priced 6,000,000 units, including pre-funded units, at $2.00 each for about $12 million. ThinkEquity is sole book-running manager, and the prospectus says the financial statements raise substantial doubt about the company's ability to continue as a going concern. ## BioVie at a glance - **Ticker**: BIVI - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $9.0 million ### Related companies - [Passage Bio](https://aibio.space/companies/passage-bio/) NASDAQ: PASG - [Allogene Therapeutics](https://aibio.space/companies/allogene-therapeutics/) NASDAQ: ALLO - [Crescent Biopharma](https://aibio.space/companies/crescent-biopharma/) NASDAQ: CBIO - [Aptevo Therapeutics](https://aibio.space/companies/aptevo-therapeutics/) NASDAQ: APVO - [Fate Therapeutics](https://aibio.space/companies/fate-therapeutics/) NASDAQ: FATE - [Oncolytics Biotech](https://aibio.space/companies/oncolytics-biotech/) NASDAQ: ONCY - [Solid Biosciences](https://aibio.space/companies/solid-biosciences/) NASDAQ: SLDB - [4D Molecular Therapeutics](https://aibio.space/companies/4d-molecular-therapeutics/) NASDAQ: FDMT ### Also on NASDAQ - [Curanex Pharmaceuticals](https://aibio.space/companies/curanex-pharmaceuticals/) CURX - [PMGC Holdings](https://aibio.space/companies/pmgc/) ELAB - [Dogwood Therapeutics](https://aibio.space/companies/dogwood-therapeutics/) DWTX - [CARLSMED, INC.](https://aibio.space/companies/carlsmed/) CARL - [Lifevantage](https://aibio.space/companies/lifevantage/) LFVN - [ImmunityBio](https://aibio.space/companies/immunitybio/) IBRX ## What BioVie does BioVie Inc. describes itself as a clinical-stage company developing drug therapies for neurological and neurodegenerative disorders and advanced liver disease. Its main program is bezisterim (NE3107), an investigational oral small molecule that the company believes inhibits inflammation-driven insulin resistance. The company is studying bezisterim in Alzheimer's disease, Parkinson's disease and Long COVID. In August 2026 BioVie announced topline results from its Phase 2b SUNRISE-PD trial, a randomized, double-blind, placebo-controlled study of bezisterim 20 mg twice daily in 57 patients with early-stage Parkinson's disease who were naive to symptomatic dopaminergic therapy. The company said the trial met its prespecified primary endpoint on a panel of blood-based inflammatory markers. It described bezisterim as well tolerated, while noting that the results are preliminary and that the biomarker endpoints are not validated surrogate endpoints. The company intends to use the results to inform the design of a potentially pivotal Phase 3 registrational trial in Parkinson's disease. Its earlier Phase 2 study in Parkinson's disease was completed in December 2022. | Product or program | What it is | Stage | |---|---|---| | Bezisterim (NE3107) | Oral small molecule studied in Alzheimer's, Parkinson's and Long COVID | Phase 2b topline results reported | Summarised from the company's [10-K filed Aug 13, 2026](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000332/bivi-20260630_10kv8.htm). ## BioVie annual financials | Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 | |---|---|---| | Research and development | [$14.0 million](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000332/) | [$9.3 million](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000332/) | | Net income (loss) | [-$22.1 million](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000332/) | [-$17.5 million](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000332/) | | Cash from operations | [-$19.0 million](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000332/) | [-$19.0 million](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000332/) | | Cash and equivalents | [$9.0 million](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000332/) | [$17.5 million](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000332/) | Latest balance sheet, Jun 30, 2026 (10-K): cash and equivalents $9.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about BioVie Has BioVie issued a going-concern warning? Our latest story on this, dated Aug 8, 2025: "BioVie prices $12 million public offering of units at $2.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/biovie-prices-12-million-public-offering-units-2-00/). Has BioVie raised money recently? Our latest story on this, dated Sep 11, 2026: "BioVie enters sales agreement for up to $6,464,341 of common stock". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/biovie-enters-sales-agreement-up-6-464-341-common-stock/). Is BioVie involved in a lawsuit? Our latest story on this, dated Aug 13, 2026: "BioVie securities class certified in Nevada; three derivative suits stayed". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/biovie-securities-class-certified-nevada-three-derivative-suits-stayed/). What is the ticker symbol of BioVie? BioVie Inc. trades under the ticker BIVI on NASDAQ. Where is BioVie listed? BioVie Inc. is listed on NASDAQ. What is the SEC CIK of BioVie? The SEC Central Index Key (CIK) for BioVie Inc. is 1580149. Its filings are on SEC EDGAR. How many shares does BioVie have outstanding? 7,542,638 shares as of 2026-08-10, per the cover page of its 10-K filed 2026-08-13. Which country or territory is BioVie listed under? Our directory records BioVie Inc. under United States. What does BioVie do? Our directory classifies BioVie Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of BioVie? The ISIN recorded for BioVie Inc. is US09074F5044. Does aibio.space cover BioVie? aibio.space lists BioVie Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is BioVie incorporated? SEC records list its state or country of incorporation as NV. What does BioVie develop? BioVie Inc. describes itself as a clinical-stage company developing drug therapies for neurological and neurodegenerative disorders and advanced liver disease. Its main program is bezisterim (NE3107), an investigational oral small molecule that the company believes inhibits inflammation-driven insulin resistance. What is Bezisterim (NE3107) from BioVie? Bezisterim (NE3107): Oral small molecule studied in Alzheimer's, Parkinson's and Long COVID Stage: Phase 2b topline results reported. Is BioVie profitable? BioVie Inc. reported a net loss of $22.1 million for the fiscal year ended Jun 30, 2026, and used $19.0 million of cash in operations, per its annual report to the SEC. ## Investor discussion: BioVie Members talk about BioVie (BIVI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at BioVie, newest first. Each line links the filing it comes from. 1. 2026-09-14 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000389/bivi-424b5.htm) 2. 2026-08-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000332/bivi-20260630_10kv8.htm) 3. 2026-07-17 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000276/bivi_s1.htm) 4. 2025-08-15 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1580149/000152013825000268/bivi-20250630_10k.htm) 5. 2025-08-08 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1580149/000152013825000247/bivi_424b5.htm) 6. 2025-07-03 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1580149/000152013825000198/bivi_s1.htm) 7. 2025-06-27 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03). [Source](https://www.sec.gov/Archives/edgar/data/1580149/000152013825000190/bivi-20250626_8k.htm) 8. 2025-06-24 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1580149/000152013825000185/bivi-20250623_8k.htm) 9. 2025-06-02 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1580149/000152013825000166/bivi-def14a.htm) 10. 2025-05-08 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1580149/000152013825000142/bivi-pre14a.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BIVI on TradingView](https://www.tradingview.com/symbols/NASDAQ-BIVI/). ## SEC filings and registration - **SEC name**: Biovie Inc. - **CIK**: 1580149 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BIVI (Nasdaq), BIVIW (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 680 W NYE LANE, CARSON CITY, NV, 89703 - **Phone**: 775-888-3162 - **Shares outstanding**: 7,542,638 as of 2026-08-10 (10-K filed 2026-08-13) - **Former names**: NANOANTIBIOTICS, INC. ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000395/bivi-def14a.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000391/bivi-20260911_8k.htm) filed 2026-09-14 - [424B5](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000389/bivi-424b5.htm) filed 2026-09-14 - [10-K](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000332/bivi-20260630_10kv8.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000312/bivi-20260806_8k.htm) filed 2026-08-06 - [S-1](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000276/bivi_s1.htm) filed 2026-07-17 - [S-3](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000244/bivi_s3.htm) filed 2026-06-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000154/bivi-20260331_10q.htm) filed 2026-05-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001580149), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details BioVie Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BIVI, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: BioVie Inc. - **Ticker**: BIVI - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US09074F5044 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BIVI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/biovie/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BioVie (BIVI) news: going concern, offering and lawsuit", 2026-10-31, https://aibio.space/companies/biovie/